Transplantation therapy for Parkinson's disease

Expert Opinion on Investigational Drugs

Volumn 9, Issue 10, 2000, Pages 2319-2330

  Borlongan, C V ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

Clinical trials; Immunosuppression; Intracerebral grafts; Neurodegenerative disorders; Parkinson's disease; Trophic factors

Indexed keywords

1 (3,3 DIMETHYL 1,2 DIOXOPENTYL) 2 PYRROLIDINECARBOXYLIC ACID 3 (3 PYRIDYL)PROPYL ESTER; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 6 FLUORODOPA; CYCLOSPORIN A; DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; IMMUNOSUPPRESSIVE AGENT; LEVODOPA; NEUROPROTECTIVE AGENT; NEUROTROPHIC FACTOR; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; V 10 367;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; BRAIN TRANSPLANTATION; CLINICAL PRACTICE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG ACTIVITY; FETUS; GRAFT REJECTION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL ASSESSMENT; MEDICAL RESEARCH; NERVOUS TISSUE; NONHUMAN; PARKINSON DISEASE; PRIMATE; RAT; REVIEW; TISSUE TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0033809950     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.10.2319     Document Type: Review

References (67)

1. Fetal tissue grafting into the central nervous system: Yesterday, today and tomorrow
2. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system
3. Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants
4. Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with intractable Parkinson's disease
5. Chromaffin cell survival and host dopaminergic fiber recovery in a patient with Parkinson's disease treated by cografts of adrenal medulla and pretransected peripheral nerve. Case report
6. Long-term enhanced chromaffin cell survival and behavioral recovery in hemiparkinsonian rats with co-grafted polymer-encapsulated human NGF-secreting cells
7. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
8. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease
9. Fifteen months follow-up on bilateral embryonic mesencephalic grafts in two cases of severe MPTP-induced parkinsonism
10. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up
11. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient
12. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease
13. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease
14. Human fetal tissue transplantation
15. The influence of donor age on the survival of solid and suspension intraparenchymal human embryonic nigral grafts
16. MRI-stereotactical approach for neural grafting in basal ganglia disorders
17. Outcome following intrastriatal fetal mesencephalic grafts for Parkinson's patients is directly related to the volume of grafted tissue
18. Survival of implanted fetal dopamine cells and neurologic improvements 12 to 46 months after transplantation for Parkinson's disease
19. Complex sensorimotor behavioral changes after terminal striatal 6-OHDA lesion and transplantation of dopaminergic embryonic micrografts
20. Constructing a new nigrostriatal pathway in the Parkinsonian model with bridged neural transplantation in substantia nigra
21. Functional and anatomical reconstruction of the 6-hydroxydopamine lesioned nigrostriatal system of the adult rat
22. Basic neural transplantation techniques. I. Dissociated cell suspension grafts of embryonic ventral mesencephalon in the adult rat brain
23. Medial fetal ventral mesencephalon: A preferred source for dopamine neuron grafts
24. Differential dissection of the rat E16 ventral mesencephalon and survival and reinnervation of the 6-OHDA-lesioned striatum by a subset of aldehyde dehydrogenase-positive TH neurons
25. Co-grafted embryonic striatum increases the survival of grafted embryonic dopamine neurons
26. Hitchcock's experimental series of foetal implants for Parkinson's disease: Co-grafting ventral mesencephalon and striatum
27. Strands of embryonic mesencephalic tissue show greater dopamine neuron survival and better behavioral improvement than cell suspensions after transplantation in parkinsonian rats
28. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease
29. Improving the survival of grafted dopaminergic neurons: A review over current approaches
30. Treatment strategies for neurodegenerative diseases based on trophic factors and cell transplantation techniques
31. Neurotrophic actions of non-immunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A
32. Neural actions of immunophilin ligands
33. A novel immunophilin ligand: Distinct branching effects on dopaminergic neurons in culture and neurotrophic actions after oral administration in an animal model of Parkinson's disease
34. Immunophilin ligands and GDNF enhance neurite branching or elongation from developing dopamine neurons in culture
35. CNS immunological modulation of neural graft rejection and survival
36. Cyclosporine A-induced hyperactivity in rats: Is it mediated by immunosuppression, neurotrophism, or both?
37. Cyclosporine-A enhances choline acetyltransferase immunoreactivity in the septal region of adult rats
38. Cyclosporin A attenuates the decrease in tyrosine hydroxylase immunoreactivity in nigrostriatal dopaminergic neurons and in striatal dopamine content in rats with intrastriatal injection of 6-hydroxydopamine
39. FK506 and cyclosporin A enhance the survival of cultured and grafted rat embryonic dopamine neurons
40. Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntingdon's diseases
41. Intrastriatal ventral mesencephalic xenografts of porcine tissue in rats: Immune responses and functional effects
42. Testis-derived Sertoli cells survive and provide localized immunoprotection for xenografts in rat brain
43. Therapeutic potential of a polymer-encapsulated L-DOPA and dopamine-producing cell line in rodent and primate models of Parkinson's disease
44. A novel mode of immunoprotection of neural xenotransplants: Masking of donor major histocompatibility complex class I enhances transplant survival in the central nervous system
45. Intrastriatal transplantation of rat adrenal chromaffin cells seeded on microcarrier beads promotes long-term functional recovery in hemiparkinsonian rats
46. Long-term viability of isolated bovine adrenal medullary chromaffin cells following intrastriatal transplantation
47. Purification of adrenal chromaffin cells increases antinociceptive efficacy of xenotransplants without immunosuppression
48. Neurturin and glial cell line-derived neurotrophic factor receptor-beta (GDNFR-beta), novel proteins related to GDNF and GDNFR-alpha with specific cellular patterns of expression suggesting roles in the nervous system and in peripheral organs
49. Intracerebral transplantation of testis-derived sertoli cells promotes functional recovery in female rats with 6-hydroxydopamine-induced hemiparkinsonism
50. Testis-derived Sertoli cells have a trophic effect on dopamine neurons and alleviate hemiparkinsonism in rats
51. Cellular and functional recovery of Parkinsonian rats after intrastriatal transplantation of carotid body cell aggregates
52. Kidney cografts enhance fiber outgrowth from ventral mesencephalic grafts to the 6-OHDA-lesioned striatum and improve behavioral recovery
53. Transplantation of autologous sympathetic ganglion into the brain with Parkinson's disease. Long-term follow-up of 35 cases
54. Porcine xenografts in Parkinson's disease and Huntington's disease patients: Preliminary results
55. Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease
56. Transplantation of cryopreserved human embryonal carcinoma-derived neurons (NT2N cells) promotes functional recovery in ischemic rats
57. Engraftable human neural stem cells respond to developmental cues, replace neurons and express foreign genes
58. GDNF increases the density of cells containing calbindin but not of cells containing calretinin in cultured rat and human fetal nigral tissue
59. Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts
60. GDNF enhances dopaminergic cell survival and fibre outgrowth in embryonic nigral grafts
61. Neuronenriched second trimester human cultures: Growth factor response and in vivo graft survival
62. Preliminary voice and speech analysis following fetal dopamine transplants in 5 individuals with Parkinson's disease
63. Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach
64. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment
65. Functional MRI of apomorphine activation of the basal ganglia in awake rhesus monkeys
66. Neural transplantation for neurodegenerative disorders
67. Cell replacement therapies for central nervous system disorders